Results 31 to 40 of about 1,997 (174)

X-linked ubiquitin-specific peptidase 11 (USP11) increases susceptibility to Cushing’s disease in women [PDF]

open access: yesActa Neuropathologica Communications
The incidence of pituitary adrenocorticotropic hormone (ACTH)-secreting PitNETs, commonly known as ACTH PitNETs, is significantly higher in females; however, the underlying causes for this gender disparity remain unclear.
Tao Zhang   +8 more
doaj   +2 more sources

EFFICACY AND SAFETY OF LOMITAPIDE IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: THE PAN-EUROPEAN RETROSPECTIVE OBSERVATIONAL STUDY [PDF]

open access: yes, 2021
Background: Lomitapide is a lipid-lowering agent indicated as adjunct therapy for adult HoFH. Objectives: This study evaluated the medium-term effectiveness and safety of lomitapide in a large cohort of HoFH patients in Europe.
Anja Vogt   +56 more
core   +3 more sources

Efficacy and Safety of Lomitapide in Homozygous Familial Hypercholesterolaemia: A Systematic Review

open access: yesReviews in Cardiovascular Medicine, 2022
Background: Homozygous familial hypercholesterolaemia (HoFH) patients have little or no low-density lipoprotein receptor (LDLR) function. HMG-CoA (3-hydroxy-3-methyl glutaryl coenzyme A) reductase inhibitors (statins) and proprotein convertase subtilisin/
Namin Wei   +8 more
doaj   +1 more source

Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma. [PDF]

open access: yesCancer Rep (Hoboken)
ABSTRACT Background Glioblastoma (GB) is the most aggressive primary malignant brain tumor in adults and remains associated with poor survival despite surgical resection followed by radiotherapy and temozolomide (TMZ) chemotherapy. Intrinsic and acquired resistance to TMZ, including MGMT‐dependent DNA repair and activation of pro‐survival pathways ...
Nakhaei A   +5 more
europepmc   +2 more sources

Antibacterial activities and action mode of anti-hyperlipidemic lomitapide against Staphylococcus aureus

open access: yesBMC Microbiology, 2022
Background The increasing emergence of multidrug-resistant Gram-positive bacterial infections necessitates new antibacterial agents with novel mechanisms of action that can be used to treat these infections.
Yufang Zhang   +10 more
doaj   +1 more source

Case report: Therapy adherence, MTTP variants, and course of atheroma in two patients with HoFH on low-dose, long-term lomitapide therapy

open access: yesFrontiers in Genetics, 2023
Background: Homozygous familial hypercholesterolemia (HoFH) is a rare and devastating genetic condition characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) leading to an increased risk of premature atherosclerosis ...
Meral Kayikcioglu   +4 more
doaj   +1 more source

Assessment of the global and national market for lipid modifying agents: retrospective and innovation

open access: yesСибирский научный медицинский журнал, 2023
Lipid-lowering therapy is one of the most important aspects in the treatment of patients with cardiovascular disease, which is still the leading cause of death in the adult population.
A. V. Lokhmacheva   +3 more
doaj   +1 more source

Blueberries Reduce Palm Oil-Induced Metabolic Endotoxemia in an In Vitro Human Intestinal-Immune Cell Model. [PDF]

open access: yesMol Nutr Food Res
Digested palm oil and LPS treatment on intestinal Caco‐2 cells results in palm oil‐induced LPS translocation across the intestinal cell monolayer and nuclear factor kappa B (NF‐κB) activation of basolateral macrophages. Interestingly, digested whole berries reduce the palm oil + LPS‐mediated NF‐κB activation in macrophages.
Casademont-Roca A   +5 more
europepmc   +2 more sources

THE IMPACT OF EVINACUMAB THERAPY ON PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM PART B OF A PHASE 3 TRIAL

open access: yesAmerican Journal of Preventive Cardiology, 2023
Therapeutic Area: ASCVD /CVD Risk Reduction Background: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels.
Albert Wiegman   +15 more
doaj   +1 more source

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

open access: yesAtherosclerosis Plus, 2021
Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels.
Maria Giovanna Lupo   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy